Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar 9;115(3):242-245.
doi: 10.1093/jnci/djac228.

A predictor of response in HER2+ breast cancer-at last!

Sunil S Badve  1 , Yesim Gökmen-Polar  1
Affiliations
Editorial

A predictor of response in HER2+ breast cancer-at last!

Sunil S Badve et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Complex biology of HER2-related breast cancers. Response to therapy is multifactorial and impacted by patient variable, HER2 expression, and its interaction with other molecular pathways as well as by the therapeutic regimens prescribed for the patient.
See this image and copyright information in PMC

Comment on

  • HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
    Brasó-Maristany F, Griguolo G, Chic N, Pascual T, Paré L, Maues J, Galván P, Dieci MV, Miglietta F, Giarratano T, Martínez-Sáez O, Marín-Aguilera M, Schettini F, Conte B, Angelats L, Vidal M, Adamo B, Muñoz M, Sanfeliu E, González B, Vivancos A, Villagrasa P, Parker JS, Perou CM, Conte P, Prat A, Guarneri V. Brasó-Maristany F, et al. J Natl Cancer Inst. 2023 Mar 9;115(3):332-336. doi: 10.1093/jnci/djac227. J Natl Cancer Inst. 2023. PMID: 36576009 Free PMC article.

References

    1. Swain SM, Shastry M, Hamilton E.. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2022;1-26. - PMC - PubMed
    1. Ruschoff J, Friedrich M, Nagelmeier I, et al. Comparison of HercepTest mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status. Virchows Arch. 2022;481(5):685-694. - PMC - PubMed
    1. Schalper KA, Kumar S, Hui P, et al. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria. Arch Pathol Lab Med. 2014;138(2):213-219. - PubMed
    1. Wu NC, Wong W, Ho KE, et al. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform. Breast Cancer Res Treat. 2018;172(2):327-338. - PMC - PubMed
    1. Wesseling J, Tinterri C, Sapino A, et al. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer. Virchows Arch. 2016;469(3):297-304. - PubMed

Substances